Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AHS 2022 | The development of more targeted therapies for headache

Lauren Natbony, MD, Icahn School of Medicine, New York, NY, discusses unanswered questions in headache care and treatment. CGRP is the protein that has most recently been studied for targeted medication – however, with some individuals not responding well to CGRP targeted medications, it is evident that other proteins are driving migraine attacks. Therefore, there is a need for a greater understanding of individual biochemistry – allowing for more targeted therapies. This interview took place during the 2022 American Headache Society (AHS) Annual Scientific Meeting in Denver, CO.